5 results about "OPHTHALMIC DISORDERS" patented technology

This invention discloses the application of LGK974 in the preparation of drugs for the prevention and / or treatment of dry eye syndrome, relating to the field of biomedical technology. The application of LGK974 in the preparation of drugs for the prevention and / or treatment of dry eye syndrome. This invention is the first to discover the application of the Wnt-β-catenin pathway inhibitor LGK974 in the treatment of dry eye syndrome. LGK974, by inhibiting the Wnt-β-catenin pathway, can effectively protect meibomian gland acini and ducts, restoring normal lipid metabolism and secretion. In a NOD (Normally Ophthalmic Disorder) Sjögren's syndrome model, oral administration of 200-400 μg / kg / day of LGK974 significantly improved dry eye symptoms, including reduced corneal defects and increased tear secretion, alleviating morphological and functional damage to the meibomian glands. LGK974 provides a new targeted strategy for the treatment of dry eye syndrome, especially Sjögren's syndrome-related dry eye syndrome and meibomian gland dysfunction-related dry eye syndrome, and may become a potent and effective drug for the clinical treatment of dry eye in the future.

The present invention relates to compounds of formula (I) or a stereoisomer or tautomer thereof, (I) wherein n, q, A1, A2, A3, A4, L1, L2, B1 and B2 have the same meaning as those defined in the claims and the description. The present application also relates to compositions, in particular medicaments, comprising such compounds, and to the use of such compounds and compositions for the prevention and / or treatment of conditions that can be treated with nuclear export protein 1 (XPO1) inhibitors, the disorders are, for example, proliferative disorders, cancer, inflammatory disorders, autoimmune disorders, viral infections, ophthalmic disorders, neurodegenerative disorders, abnormal tissue growth disorders, disorders associated with food intake, allergies, respiratory diseases, dermatological syndromes, solar injury, congestive heart failure, and hypertrophic cardiomyopathy, trauma and spinal cord injury.

The present invention relates to a combination of nerve growth factor and sesamin, and uses thereof in the treatment of ophthalmic disorders.

Described herein are methods and devices for the long term treatment of ophthalmic disorders. Also disclosed are encapsulated cell therapy (ECT) devices that secrete a biologically active molecule and methods for using the same for the treatment of various kinds of ophthalmic disorders, including retinitis pigmentosa, geographic atrophy (dry age-related macular degeneration), glaucoma and / or macular telangiectasia.